Bristol-Myers to Stop New Antiviral Drug Research

A sign stands in front of the Bristol-Myers Squib Company's headquarters in Lawrence Township in 2005. (AP Photo/Mel Evans)
A sign stands in front of the Bristol-Myers Squib Company's headquarters in Lawrence Township in 2005. (AP Photo/Mel Evans)
A sign stands in front of the Bristol-Myers Squib Company’s headquarters in Lawrence Township in 2005. (AP Photo/Mel Evans)

 

(Reuters) – Bristol-Myers Squibb said on Thursday that it would stop efforts to find new antiviral drugs and cut 100 related jobs.

The company said it will also discontinue its Hepatitis B and HIV early programs.

Bristol-Myers said already marketed products and its ongoing clinical programs in virology would not be hit by the decision.

The company is seeking U.S. approval for its experimental hepatitis C drug, daclatasvir.

READ MORE

Be the first to comment

Leave a Reply

Your email address will not be published.


*


This site uses Akismet to reduce spam. Learn how your comment data is processed.